Partner content
How we can continue to innovate in the care of rare diseases
The UK has a compelling offer in cutting-edge science, but more must be done to realise its potential.
ByPharmaceuticals
Medicine wars
A revolt over patient safety and declining expertise is tearing the medical establishment apart.
By
Craig Ritchie: “Dementia is a crisis of our own making”
The psychiatrist and renowned brain health expert on changing perceptions around the UK’s biggest killer.
By
I’m a community pharmacist – we’ve been overlooked for too long
High street pharmacies are more than just chemist shops – they give patients access to life-saving advice and medical care.
By
Partner content
Individually rare, collectively common – how do we transform the lives of people with rare diseases?
Clear national policy, collaboration with patients, and reviewing progress are key to tackling diagnosis, treatment and care challenges.
How the UK-India trade deal threatens affordable medicines
The government is pushing for strengthened intellectual property rules for India-made pharmaceuticals.
By
Do healthcare guidelines prioritise consistency over patient care?
Nice needs to lead the debate about treatments that may be too low-value to justify using NHS resources.
By
Partner content
How to turn the life sciences “superpower” ambition into reality
Partnership between the NHS, industry and research institutes is crucial to enable the UK to reach its clinical research potential.
By
Partner content
How can the UK boost its life sciences sector to improve patient outcomes?
Britain has a strong background in pharmaceuticals and clinical trials but is struggling to achieve its full potential.
Partner content
Strengthening the UK’s clinical trial ecosystem
Why pharmaceutical companies play a role in driving progress.
By
Partner content
How digital innovation can unlock a healthier future
The rapid advancement of technology must be used to fight disease.
By
Partner content
It’s time to talk about psoriasis
We urgently need more dermatology specialists and a greater focus on skin conditions.
Partner content
Making the UK the prime destination for the life sciences
Cross-sector working, NHS resourcing and strong leadership are all needed to propel us in medicine development.
£2.5bn extra to Big Pharma? Don’t tell striking NHS staff
The expiration of Vpas, the health department-private sector agreement, could see the NHS's medicines bill ballooning.
By
Health data must be used in the public interest
Access to anonymised health records could transform the treatment of disease, but only if it’s done ethically.
By
Partner content
How can innovation improve NHS capacity?
Could investing in new technologies optimise patient outcomes and address current workforce challenges?
Placing more trust in pharmacists will ease pressure on GPs
Utilising pharmacy’s expertise will be vital in providing better patient care and reducing the backlog.
By
Pharma companies call for national vaccination strategy
The life sciences industry has told MPs that the UK needs to tackle declining immunisation rates and anti-vax attitudes.
By
Joanna Moncrieff: “I’m not convinced antidepressants have any use”
The controversial psychiatrist on taking on the pharmaceutical firms, and how Covid made it “OK to cancel scientists”.
By
The great attention deficit: what’s fuelling the rise in adult ADHD?
No longer confined to “problem children”, ADHD diagnoses are booming – yet it’s a condition that remains widely misunderstood.
By- 1
- 2